News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
News UK grants patients early access to AbbVie/Roche leukaemia dr... Venetoclax still under review in Europe.
Clinical AbbVie/Roche's Venclexta produces complete remission in 10% ... AbbVie/Roche's Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, a sub-group who do not respond well
Views & Analysis Obstacles to true patient centricity in Europe Campaigner and cancer patient Andrew Schorr says pharma needs to knock down the barriers to greater patient influence.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
